Handelsavisen
prelaunch
Companies Healthcare GTHP.PK
GT
GTHP.PK OTC Advanced Medical Equipment & Technology

Gthp.Pk

$0,28
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-366,2 %
ROE
53,2 %
Net margin
-416,7 %
Debt / equity
-0,37
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

GTHP.PK operates in the Advanced Medical Equipment & Technology industry, providing specialized healthcare services and equipment.

Business. GTHP.PK operates in the Advanced Medical Equipment & Technology industry, providing specialized healthcare services and equipment.

Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
53,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning GTHP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to GTHP.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    GTHP.PK operates in the Advanced Medical Equipment & Technology industry, providing specialized healthcare services and equipment.

    Classification99 %
    SectorHealth Care
    Industry groupAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    GTHP.PK exhibits a highly leveraged capital structure, with total liabilities of $7.33 million and total equity of -$6.01 million, resulting in a negative debt-to-equity ratio of -0.37. The company's liquidity position is weak, with a current ratio of 0.09 and only $63,000 in cash and equivalents. This suggests a high liquidity risk, as the company may struggle to meet short-term obligations without external financing.

    Profitability metrics are severely negative, with a net loss of $3.196 million and an operating loss of $2.809 million. The return on equity of 53.21% is misleading due to the negative equity base, and the return on assets of -2.41% indicates poor asset utilization. These figures fall well below the industry median for profitability and returns, highlighting a significant underperformance relative to peers.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to sector-specific risks and limits growth opportunities. There is no available data on geographic revenue distribution, but the absence of segment reporting suggests a high concentration risk.

    GTHP.PK's growth trajectory is uncertain, with no disclosed revenue growth or outlook provided in the available data. The company reported a revenue of $767,000, but without historical comparisons or forward-looking guidance, it is difficult to assess future performance. The negative operating and net income figures suggest a lack of sustainable growth drivers.

    The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential cash flow constraints. There is no indication of recent dilutive events, and the diluted shares outstanding are equal to the basic shares, indicating no near-term dilution pressure.

    Recent events and filings are not disclosed in the available data, making it difficult to assess any material developments or strategic shifts. The absence of recent transcripts or filings limits the ability to evaluate management's strategy or operational performance.

    Key takeaways
    • GTHP.PK has a highly leveraged capital structure with a negative equity position and weak liquidity.
    • The company is unprofitable, with significant operating and net losses, and underperforms industry peers on key profitability metrics.
    • Revenue is concentrated in a single segment, with no geographic diversification disclosed, increasing exposure to sector-specific risks.
    • Growth prospects are unclear due to the lack of historical revenue data and forward-looking guidance.
    • Liquidity risk is medium, and dilution risk is low, but the company's negative net cash position is a key concern.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,28
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$6.0M
    Net cash
    -$2.2M
    Current ratio
    0.1
    Debt / equity
    -0.4
    ROA
    -2.4%
    ROE
    53.2%
    Cash conversion
    33.0%
    CapEx / revenue
    -0.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryAdvanced Medical Equipment & Technology170,9B node revenueTMO 26,1%DHR 14,4%GEHC 12,1%PHG 11,9%BSX 11,7%ISRG 5,9%A 4,1%EW 3,5%Other 10,4%
    Source: company disclosures · own-taxonomy revenue-covered setGTHP 0,0% · rank #39 of 46

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs GTHP · multiples and returns
    TM
    TMO
    Thermo Fisher Scientific Inc
    $574,03
    214,1B USD
    P/E
    29,4x
    vs self
    Div yield
    0,3 %
    vs self
    ROE
    12,9 %
    vs self
    DH
    DHR
    Danaher Corp
    $197,50
    140,1B USD
    P/E
    38,2x
    vs self
    Div yield
    vs self
    ROE
    6,9 %
    vs self
    GE
    GEHC
    GE HEALTHCARE TECHNOLOGIES INC.
    $69,72
    31,9B USD
    P/E
    13,6x
    vs self
    Div yield
    0,2 %
    vs self
    ROE
    19,5 %
    vs self
    PH
    PHG
    PHG
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BS
    BSX
    Boston Scientific Corp
    $48,54
    72,6B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    IS
    ISRG
    INTUITIVE SURGICAL, INC.
    $376,00
    133,2B USD
    P/E
    287,7x
    vs self
    Div yield
    vs self
    ROE
    3,6 %
    vs self
    A
    A
    Agilent Technologies Inc
    $139,80
    39,6B USD
    P/E
    29,0x
    vs self
    Div yield
    0,8 %
    vs self
    ROE
    19,3 %
    vs self
    EW
    EW
    Edwards Lifesciences Corp
    $88,82
    51,6B USD
    P/E
    44,3x
    vs self
    Div yield
    vs self
    ROE
    10,4 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-366,2 %Bottom quartile
    Net Margin-416,7 %Bottom quartile
    ROE53,2 %Best in class
    Capex / Rev-0,3 %Above P75
    D/E-0,37Best in class
    Cash Conv0,33Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • GTHP.PK Market data — financials · 2026-05-28

    Ownership & reference

    Leadership

    • Mark L. FaupelPresident, Chief Executive Officer, Director

    Insider activity

    — missing data

    Short positioning

    1.4Kshares short-92.7% vs prior
    1days to cover
    377fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    GTHP.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Return on equity (FY 2025-12-31): 53.2%Derived (calculated)
    • Gross margin (FY 2025-12-31): 74.4%Derived (calculated)
    • Net margin (FY 2025-12-31): -416.7%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 20.0%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 4.6%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): 28,450.0%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -32.2%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 3,820.0%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 20.0%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): -1.22xDerived (calculated)
    • Current ratio (FY 2025-12-31): 0.09xDerived (calculated)
    • Return on assets (FY 2025-12-31): -241.4%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -12.5%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 10,857.1%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -22.8%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -3.9%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 17.0%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -10.8%Derived (calculated)
    • Capex (annual): USD 2KSEC XBRL filing
    • Shareholders' equity (annual): USD -6.01MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
    • R&D expense (annual): USD 469KSEC XBRL filing
    • Operating cash flow (annual): USD -1.07MSEC XBRL filing
    • Revenue (annual): USD 767KSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage